STOCK TITAN

Aquestive Therapeutics Inc - AQST STOCK NEWS

Welcome to our dedicated news page for Aquestive Therapeutics (Ticker: AQST), a resource for investors and traders seeking the latest updates and insights on Aquestive Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aquestive Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aquestive Therapeutics's position in the market.

-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.72%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.55%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.25%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.55%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.41%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.81%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.59%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.99%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.98%
Tags
Aquestive Therapeutics Inc

Nasdaq:AQST

AQST Rankings

AQST Stock Data

346.38M
65.02M
5.03%
34.33%
2.53%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States
Warren

About AQST

aquestive therapeutics is a specialty pharmaceutical company that advances and commercializes medicines to solve critical healthcare problems and meaningfully improve people’s lives. our team asks questions and identifies issues others have not, and builds solutions that empower patients and their caregivers with better ways to manage complex diseases. our initial focus, supported by our current approved products and late stage pipeline, is to address immediate cns challenges.